United States· US:0078-0734_45376297-5629-4f69-a583-48a97e905a82
Ilaris
A medicinal product containing canakinumab, registered in United States by Novartis Pharmaceuticals Corporation.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- canakinumab
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1100780734611 VIAL, SINGLE-USE in 1 CARTON (0078-0734-61) / 1 mL in 1 VIAL, SINGLE-USE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Canakinumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceILARIS 150 mg/ml, solution injectableNOVARTIS EUROPHARM (IRLANDE)
- IrelandIlaris 150 mg/ml solution for injectionNovartis Europharm Limited
- NetherlandsIlaris 150 mg/ml, oplossing voor injectieNovartis Europharm Limited
- BelgiumIlaris 150 mgNovartis Europharm
- CzechiaILARISNovartis Europharm Limited, Dublin
- SwedenIlaris 150 mg Injektionsvätska, lösning i förfylld injektionspennaNovartis Europharm Limited
- IcelandIlarisNovartis Europharm Limited*
- United KingdomIlaris 150mg powder for solution for injection vialsNovartis Pharmaceuticals UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ilaris
- Liechtenstein · Ilaris
- Norway · Ilaris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/72a179f6-56a5-4997-8cd9-0c3855eefdca GET /v1/drugs/72a179f6-56a5-4997-8cd9-0c3855eefdca?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"productid": "0078-0734_45376297-5629-4f69-a583-48a97e905a82",
"productndc": "0078-0734",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "CANAKINUMAB",
"proprietary_name": "Ilaris",
"active_ingred_unit": "mg/mL",
"application_number": "BLA125319",
"marketing_category": "BLA",
"nonproprietary_name": "canakinumab",
"start_marketing_date": "20161222",
"active_numerator_strength": "150"
}See everything about canakinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.